Achievement of Control of Severe Bronchial Asthma When Using Dupilumab

   The aim of the study was to evaluate the possibility of achieving control of severe bronchial asthma (BA) using genetically engineered biological therapy with Dupilumab.

   Materials and methods. The study included 32 patients with severe bronchial asthma (8 (25 %) men, mean age 58 [28; 65]) years, 24 (75 %) women, mean age 50 [26; 62] years) who received additional therapy with Dupilumab for 12 months. The endpoint of the study was 12 months of therapy with Dupilumab. The allergic phenotype of the disease was recorded in 19 (60 %) patients, a quarter of patients had non-allergic phenotype, and 5 (15 %) patients had mixed BA.

   Results. Before the introduction of genetically engineered biological therapy, patients had an extremely high daily need for emergency medications — about 9 times a day, 4 or more exacerbations were recorded during the previous 12 months before inclusion in the study. After 12 months of additional therapy with Dupilumab, a significant reduction in symptoms was noted — 22 (70 %) patients did not have asthma attacks at all. In 6 patients (19 %), 1 exacerbation of bronchial asthma developed during the next 12 months, which the patients coped with independently using nebulizer therapy at home. Before the start of genetically engineered biological therapy, 10 people (31 %) received systemic glucocorticosteroids (OCS) at a dose of 10 to 5 mg of prednisolone. After 4 months, 22 (70 %) patients receiving hormonal drugs managed to stop them. After 12 months, no patients took OCS.

   Conclusion. During 12 months of additional therapy with Dupilumab, patients managed to completely stop taking OCS. Exacerbations requiring hospitalization were absent in all patients included in the study. Complete control was achieved by 22 (69 %) subjects, partial control was achieved by 10 (31 %). There was no need for short-acting beta-agonists (SABA) in 27 (85 %) subjects.

1. Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5(9): 691–706. DOI: 10.1016/S2213-2600(17)30293-X.

2. Deev I.A., Kobyakova O.S., Starodubov V.I. General morbidity of the child population of Russia (0-14 years) in 2023. Federal State Budgetary Institution “TsNIIOIZ” of the Ministry of Health of the Russian Federation. 2024; 154-156. DOI: 10.21045/978-5-94116-160-7-2024 [In Russian].

3. Chuchalin A.G. Achievements in asthma treatment in Russia in the first decade of the new millennium. Consilium Medicum (Extra issue). 2010; 11-12 [In Russian].

4. Uphoff E, Cabieses B, Pinart M, et al. A systematic review of socioeconomic position in relation to asthma and allergic diseases. Eur RespirJ. 2015. 46(2). 364–374. DOI: 10.1183/09031936.00114514.

5. Masefield S, Edwards J, Hansen K, et al. The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). Eur Respir J. 2017; 49(5): 1602295. DOI: 10.1183/13993003.02295-2016.

6. Bahadori K, Doyle-Waters MM, Marra C et al. Economic burden of asthma : a systematic review. BMC Pulm Med. 2009. 19(9). 24. DOI: 10.1186/1471-2466-9-24.

7. Mathers CD. History of global burden of disease assessment at the World Health Organization. Arch Public Health. 2020. 24. 77-78. DOI: 10.1186/s13690-020-00458-3.

8. Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019. 46:101. DOI: 10.1016/j.smim.2019.101301.

9. Global Initiative for Asthma, GINA. 2023; 200-220. [Electronic resource]. URL: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS (date of the application: 10. 08. 2024)

10. McDowell P.J., Heaney L.G. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020; 75(2):302-310. DOI: 10.1111/all.13966.

11. Rabe KF, Nair P, Brusselle G, Maspero JF et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018. 378:2475–85. DOI: 10.1056/NEJMoa1804093.

12. Wechsler ME, Ford LB, Maspero JF et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022. 10:11–25. DOI: 10.1016/S2213-2600(21)00322-2.

13. Pirogov A.B., Prikhodko A.G., Perelman Yu.M. Participation of macrophages and epithelium in the response of bronchi to a hyperosmolar stimulus in bronchial asthma. Siberian Medical Review. 2024. 64-71. DOI: 10.20333/25000136-2024-1-64-71 [In Russian].

14. Chung K.F. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016. 192-204. DOI: 10.1111/joim.12382.

15. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015. 135(2). 299-310. DOI: 10.1016/j.jaci.2014.12.1871.

16. Andrianova G.N., Karimova A.A. Pharmacoeconomics: study guide. FGBOU VO Ural State Medical University of the Ministry of Health of the Russian Federation. Ekaterinburg: Publishing house of Ural State Medical University. 2017. 196. ISBN 978-5-89895-828-2 [In Russian].

17. Yagudina, R. I. Methodological foundations of cost - effectiveness analysis. Pharmacoeconomics: theory and practice. 2014. Vol. 2, No. 2. P. 23-27. [In Russian].

18. Clinical guidelines for bronchial asthma. Ministry of Health of the Russian Federation. 2024; 60-80. [Electronic resource]. URL: http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf?ysclid=l7un7hzve9180338084 (date of the application: 01. 08. 2024) [In Russian].

19. Graham B.L., Steenbruggen I., Miller M.R. et al. Standardization of spirometry 2019. Update an official American Thoracic Society and European Respiratory Society technical statement. Am. J. Respir. Crit. Care Med. 2019. 70–88. DOI: 10.1164/rccm.201908-1590ST.

20. Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020; 50(7): 789–98. DOI: 10.1111/cea.13614.

21. Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021; 24(14): 1165–72. DOI: 10.2147/JAA.S328988.

22. Krysanov I.S., Krysanova V.S., Ermakova V.Yu. Clinical and economic analysis of the use of the drug dupilumab in severe bronchial asthma. Qualitative clinical practice. 2020; 5: 15-26. DOI: 10.37489/2588-0519-2020-5-15-26 [In Russian].